Back to top

Image: Bigstock

Bet on Rising Price-to-Earnings With 5 Top Stocks

Read MoreHide Full Article

Investors are well aware of low P/E investing and its positives. The common investor perception is that the lower the P/E, the higher will be the value of the stock. This inference is drawn on the simple logic that a stock’s current market price does not justify (or is not equivalent to) its higher earnings and therefore has room to run.

Naturally, there are very few investors who pay attention to stocks with an increasing P/E. But this often-overlooked trend can prove useful in finding great stocks. Let’s dig a little deeper.

Why Stocks with Rising P/E Can be Equally Popular

Investors should note that stock prices move in line with earnings performance. If earnings come in stronger, the price of a stock shoots up. Solid quarterly earnings and a forward guidance in turn boost earnings forecasts, leading to stronger demand for the stock and an uptrend in its price.

So, if share price is rising steadily, it means that investors are assured of the stock’s fundamental strength and expect some strong positives out of it. Also, studies have revealed that stocks have seen their P/E ratios jump over 100% from their breakout point in the cycle. So, if you can pick stocks early in their breakout cycle, you can end up seeing considerable gains.

The Winning Strategy

In order to shortlist stocks that are exhibiting an increasing P/E, we chose the following as our primary screening parameters.

EPS growth estimate for the current year is greater than or equal to last year’s actual growth

Percentage change in last year EPS should be greater than or equal to zero

(These two criteria point to flat earnings or a growth trend over the years.)

Percentage change in price over four weeks greater than the percentage change in price over 12 weeks

Percentage change in price over 12 weeks greater than percentage change in price over 24 weeks

(These two criteria show that price of the stock is increasing consistently over the said time frames.)

Percentage price change for four weeks relative to the S&P 500 greater than the percentage price change for 12 weeks relative to the S&P 500

Percentage price change for 12 weeks relative to the S&P 500 greater than the percentage price change for 24 weeks relative to the S&P 500

(Here, the case for consistent price gains gets even stronger as it displays percentage price changes relative to the S&P 500.)

Percentage price change for 12 weeks is 20% higher than or equal to the percentage price change for 24 weeks, but it should not exceed 100%

(A 20% increase in the price of a stock from the breakout point gives cues of an impending uptrend. But a jump of over 100% indicates that there is limited scope for further upside and that the stock might be due for a reversal.)

In addition, we place a few other criteria that lead us to some likely outperformers.

Zacks Rank less than or equal to 2: Only companies with a Zacks Rank #1 (Strong Buy) or 2 (Buy) can get through.

Average 20-day Volume greater than or equal to 50,000: High trading volume implies that the stocks have adequate liquidity.

Just these few factors narrowed down the universe from over 7,700 stocks to just eight.

Here are five of eight stocks that passed the screen:

BioLineRx Ltd. (BLRX - Free Report) ): This is a biopharmaceutical development company. It carries a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Proteostasis Therapeutics Inc. : This #2 Ranked company is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics to treat diseases caused by an imbalance in the proteostasis network primarily in the United States.

Vaccinex Inc (VCNX - Free Report) : This is a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and neurodegenerative diseases. The company carries a Zacks Rank #2.

Avinger Inc (AVGR - Free Report) ): It is a commercial-stage medical device company, which designs, manufactures and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease in the United States and Europe. It carries a Zacks Rank #2.

Viveve Medical Inc. (VIVE - Free Report) ): The company manufactures and markets medical devices for the non-invasive treatment of various post-partum conditions. It carries a Zacks Rank #2.

You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial to the Research Wizard today.

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


BioLineRx Ltd. (BLRX) - free report >>

Avinger, Inc. (AVGR) - free report >>

Viveve Medical, Inc. (VIVE) - free report >>

Vaccinex, Inc. (VCNX) - free report >>